Senators Richard Blumenthal (D-Conn.) and Bob Corker (R-Tenn.) have introduced the Generating Antibiotic Incentives Now Act, which is designed to spur development of new antibiotics to combat the spread of antibiotic-resistant bacteria, according to a news release.
While antibiotics are widely used by doctors to treat common infections, an increasing number of strains of bacterial infections are immune to existing antibiotics. The GAIN Act would provide incentives to increase the commercial value of innovative antibiotic drugs and streamline the regulatory process so that pioneering infectious disease products can reach patients.
Antibiotic-resistant infections are on the rise, causing tens of thousands of deaths each year and leading to $26 billion in extra costs annually to the U.S. healthcare system.
El Camino Hospital's CMO Outlines 3-Pronged Strategy for C. Diff
Study: Providers Sometimes Blame Others, Not Themselves, for Overprescribing Antibiotics
While antibiotics are widely used by doctors to treat common infections, an increasing number of strains of bacterial infections are immune to existing antibiotics. The GAIN Act would provide incentives to increase the commercial value of innovative antibiotic drugs and streamline the regulatory process so that pioneering infectious disease products can reach patients.
Sign up for our FREE E-Weekly for more coverage like this sent to your inbox!
Antibiotic-resistant infections are on the rise, causing tens of thousands of deaths each year and leading to $26 billion in extra costs annually to the U.S. healthcare system.
Related Articles on Antibiotic Resistance:
Massachusetts Eye and Ear Infirmary to Study MRSA in 5-Year $11M StudyEl Camino Hospital's CMO Outlines 3-Pronged Strategy for C. Diff
Study: Providers Sometimes Blame Others, Not Themselves, for Overprescribing Antibiotics
